QQ客服 官方微博 反馈留言

浏览/检索结果: 共8条，第1-8条 帮助 限定条件 发表日期：2020     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation 期刊论文 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 卷号: 30, 期号: 16, 页码: 6 作者:  Su, Zhicheng;  Yang, Tingyuan;  Wang, Jie;  Lai, Mengzhen;  Tong, Linjiang 收藏  |  浏览/下载：27/0  |  提交时间：2020/12/24 EGFR  NSCLC  C797S   Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026 作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong 收藏  |  浏览/下载：38/0  |  提交时间：2020/12/24 Alflutinib  NSCLC  EGFR T790M mutation  Efficacy  Safety   Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文 MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15 作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang 收藏  |  浏览/下载：40/0  |  提交时间：2020/07/01 Non-small cell lung cancer (NSCLC)  EGFR T790M  Small-molecule inhibitor  Drug resistance  Ack1   2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant 期刊论文 CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287 作者:  Hu, Xianglong;  Xun, Qiuju;  Zhang, Tao;  Zhu, Su-Jie;  Li, Qian 收藏  |  浏览/下载：46/0  |  提交时间：2020/07/01 EGFR(C797S) mutant  SARs  2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine  Clinical resistance  Fourth-generation inhibitors   Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 192, 页码: 14 作者:  Zhang, Xin;  Xu, Fang;  Tong, Linjiang;  Zhang, Tao;  Xie, Hua 收藏  |  浏览/下载：80/0  |  提交时间：2020/07/01 Epidermal growth factor receptor (EGFR)  Resistance  Proteolysis targeting chimera (PROTAC)  Protein degradation   Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer 期刊论文 ACTA PHARMACOLOGICA SINICA, 2020, 页码: 11 作者:  Liu, Xiao-yun;  Guo, Zi-tao;  Chen, Zhen-dong;  Zhang, Yi-fan;  Zhou, Jia-lan 收藏  |  浏览/下载：76/0  |  提交时间：2020/07/01 alflutinib  AST5902  metabolism  enzyme induction  drug-drug interaction   Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation 期刊论文 ONCOGENE, 2020, 卷号: 39 作者:  Jin, Ying;  Bao, Hua;  Le, Xiuning;  Fan, Xiaojun;  Tang, Ming 收藏  |  浏览/下载：26/0  |  提交时间：2020/11/26 BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation 期刊论文 THERANOSTICS, 2020, 卷号: 10, 期号: 14, 页码: 6122-6135 作者:  Yin, Weimin;  Zhao, Yuge;  Kang, Xuejia;  Zhao, Pengfei;  Zhao, Xuhong 收藏  |  浏览/下载：44/0  |  提交时间：2020/07/01 brain targeting delivery  tumor-associated macrophage  non-small cell lung cancer (NSCLC)  drug resistance  tyrosine kinase inhibitors (TKI)  EGFR T790M mutation